Retatrutide Outperforms Ozempic in Diabetes Trial
A new phase 3 trial shows retatrutide achieves superior blood sugar and weight loss results compared to Ozempic.
Updated on Oct. 28, 2026 in Diabetes
Live Poll
Would you switch to a new diabetes medication if clinical trials showed it performed better?
The phase 3 TRANSCEND-T2D-2 clinical trial involving 1,298 adults found that retatrutide therapy significantly outperformed Ozempic in reducing HbA1c levels and body weight. Patients receiving retatrutide demonstrated more substantial clinical improvements over an 80-week treatment period.
Why it matters
This trial offers a potential new treatment pathway for patients who struggle to maintain glycemic control despite using current standard medications like metformin. The results highlight a possible shift in managing type 2 diabetes by providing more potent options for both blood sugar regulation and weight management.
In the trial, 1,298 participants were randomized to receive 9 mg or 12 mg of retatrutide or 2 mg of Ozempic. The 12 mg retatrutide group achieved a 20.9% reduction in body weight compared to 9.4% in the Ozempic group.
The details
Participants in the trial were assigned to treatment groups to assess efficacy after failing to reach glycemic targets with metformin or SGLT2 inhibitors. While retatrutide showed higher efficacy, researchers noted discontinuation rates due to adverse events like nausea and diarrhea at 4.8% and 7.9% for retatrutide dosages, compared to 2.7% for Ozempic.
Timeline
The clinical study spanned a treatment duration of 80 weeks.
Health Landscape
This trial follows the established efficacy benchmarks set by the GLP-1 receptor agonist treatment standard for type 2 diabetes by testing a more potent investigational alternative. The study directly builds upon the existing clinical framework to evaluate if a new molecule can provide enhanced patient outcomes.
Patients may eventually have access to more effective medication options if this treatment receives future regulatory approval. It is important for individuals to consult with healthcare providers regarding any changes to existing diabetes management plans or potential side effects.
The takeaway
Retatrutide shows promise as a potent intervention for diabetes management, significantly exceeding current weight loss benchmarks in clinical trials. Patients should monitor for future updates regarding regulatory review and clinical availability before considering changes to their medical regimen.
Further reading
Learn more about evolving treatment options in the Diabetes section.
Live Poll
Would you switch to a new diabetes medication if clinical trials showed it performed better?
